At the news
? MIXEDIMPACT 6/10 8-K filed Apr 30, 2026 at 16:57 ET
TELA Bio reported preliminary Q1 2026 revenue of ~$19.0M, slightly above the $18.5M consensus, but the filing is dominated by a near-total board overhaul: Chairman Doug Evans and three other directors are resigning, replaced by four new directors including a non-independent Chairman nominee. The board refresh, while bringing experienced MedTech executives, introduces uncertainty about strategic direction and governance stability.
- Preliminary Q1 2026 revenue of ~$19.0M, vs $18.5M consensus and prior Q1 guidance of ~$18.5M
- Chairman Doug Evans and three other directors (Kurt Azarbarzin, Vince Burgess, Federica O'Brien) resigning effective after 2026 Annual Meeting
- Joseph Capper (CEO of MiMedx) nominated as Class I director and proposed as Chairman, not expected to qualify as independent
- Three new directors appointed: Guido Neels (EW Healthcare), Guy Nohra (Alta Partners), Paul Thomas (Prominex CEO), all deemed independent
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access